<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003528</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01839</org_study_id>
    <secondary_id>9779</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <secondary_id>CDR0000066575</secondary_id>
    <nct_id>NCT00003528</nct_id>
  </id_info>
  <brief_title>Raltitrexed in Treating Children With Refractory Acute Leukemia</brief_title>
  <official_title>A Phase I Trial of Tomudex in Children With Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of raltitrexed in treating children with refractory&#xD;
      acute leukemia. Drugs used in chemotherapy use different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose and dose limiting toxicity of raltitrexed given for&#xD;
      three weeks to children with refractory acute leukemia.&#xD;
&#xD;
      II. Determine the incidence and severity of other toxic effects of this regimen in these&#xD;
      patients.&#xD;
&#xD;
      III. Determine a safe and tolerable dose of raltitrexed, administered in this manner, to be&#xD;
      used in phase II studies.&#xD;
&#xD;
      IV. Determine the pharmacokinetics of this regimen in these patients. V. Determine if plasma&#xD;
      2' deoxyuridine concentrations are associated with raltitrexed toxicity or pharmacokinetics.&#xD;
&#xD;
      VI. Evaluate the antitumor activity of raltitrexed against recurrent leukemia.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive raltitrexed intravenously over 15 minutes once weekly for 3 weeks followed&#xD;
      by 1 week of rest. Treatment continues in the absence of disease progression and unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      In the absence of dose-limiting toxicity (DLT) in the first cohort of 6 patients treated,&#xD;
      subsequent cohorts of 6 patients each receive escalating doses of raltitrexed on the same&#xD;
      schedule. If DLT occurs in 2 of 6 patients at a given dose level, then dose escalation ceases&#xD;
      and the next lower dose is declared the maximum tolerated dose.&#xD;
&#xD;
      Patients are followed every 6 months for 4 years, then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD based on incidence of DLT graded according to CTC version 2.0</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive raltitrexed intravenously over 15 minutes once weekly for 3 weeks followed by 1 week of rest. Treatment continues in the absence of disease progression and unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltitrexed</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>D1694</other_name>
    <other_name>ICI-D1694</other_name>
    <other_name>TDX</other_name>
    <other_name>Tomudex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven acute leukemia (M3 marrow) that is refractory&#xD;
             to conventional therapy or for which no effective therapy exists&#xD;
&#xD;
          -  No CNS leukemia&#xD;
&#xD;
          -  No solid tumors&#xD;
&#xD;
          -  Performance status: Karnofsky 50-100% OR Lansky at least 50 (for infants)&#xD;
&#xD;
          -  Life expectancy: At least 8 weeks&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  SGPT less than 5 times normal&#xD;
&#xD;
          -  Normal creatinine for age OR GFR at least 70 mL/min&#xD;
&#xD;
          -  No significant systemic illness such as infection&#xD;
&#xD;
          -  No significant third space fluid collection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Recovered from acute toxic effects of prior immunotherapy&#xD;
&#xD;
          -  At least 6 months since prior bone marrow transplant with no evidence of&#xD;
             graft-versus-host disease&#xD;
&#xD;
          -  At least 10 days since prior biologic therapy&#xD;
&#xD;
          -  At least 1 week since prior growth factors&#xD;
&#xD;
          -  At least 2 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)&#xD;
             and recovered&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
          -  Recovered from acute toxic effects of all prior radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 6 months since prior substantial bone marrow radiation&#xD;
&#xD;
          -  No other concurrent anticancer therapy or investigational agents&#xD;
&#xD;
          -  No concurrent nonsteroidal anti-inflammatory agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven D. Weitman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Pediatric Oncology Group - Geneva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swiss Pediatric Oncology Group - Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>February 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2004</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

